Earnings estimates for next year have only dropped 12 cents per share after the conference call. That's not too bad considering the low single digit revenue growth that was forecast by the company. With the recent runup in the stock however, I'm not sure if EMR has a lot of upside potential at the present 49 dollar level. I'm inclined to let it come back down a few dollars in price before buying more. 49 seems a bit high considering the stock runup coupled with the lukewarm guidance going forward. I wish the guidance had been more upbeat.